“Impact of Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, Deucravacitinib, on Psoriasis in Patients With Active Psoriatic Arthritis: Results from a Phase 2 Trial”. SKIN The Journal of Cutaneous Medicine, vol. 8, no. 2, Mar. 2024, p. s383, https://doi.org/10.25251/skin.8.supp.383.